• 1
    Bedossa P, Poynard T and the Metavir Cooperative Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 1520.
  • 2
    Westin J, Lagging LM, Wejstal R, Norkans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183187.
  • 3
    Poniachik J, Bernstein DE, Reddy R, Jeffers LJ, Coelho-Little M, Civantos F, Schiff ER. The role of lapraoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568571.
  • 4
    Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 327: 523525.
  • 5
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825832.
  • 6
    Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 249255.
  • 7
    Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, van Nhieu JT, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 2733.
  • 8
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutelier A, Vidaud M, et al. for the MULTIVIRC Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 10541058.
  • 9
    McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 15161522.
  • 10
    Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 12501257.
  • 11
    Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht, JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32: 400404.
  • 12
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760764.
  • 13
    Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868872.
  • 14
    Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000; 95: 15451550.
    Direct Link:
  • 15
    Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734739.
  • 16
    Park GJ, Lin BP, Ngu MC, Jones, DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15: 386390.
  • 17
    Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 23282332.
    Direct Link:
  • 18
    Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 31423146.
    Direct Link:
  • 19
    Sheth S, Flamm S, Gordon F, Chopra S, AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 4448.
    Direct Link:
  • 20
    Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepatitis 1997; 4: 199208.
  • 21
    Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C—a study of 527 patients at one establishment. J Viral Hepatitis 2000; 7: 268275.
  • 22
    Oberti F, Valsesia E, Pilette C, Rousseler MC, Bedossa P, Aube C, Gallois Y, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 16091616.
  • 23
    Lok AS, Everhart J, Everson G, Wright E, Sterling R, Ghany MG, Goodman Z, and the HALT-C trial investigators. Clinical model to predict cirrhosis in patients with fibrotic stages of chronic hepatitis C: an analysis of the HALT-C patient population. Hepatology 2002 (in press).
  • 24
    Pilette C, Oberti F, Aube C, Rousseler MC, Bedossa P, Gallois Y, Rifflet H, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol 1999; 31: 867873.
  • 25
    Degos F, Christidis C, Ganne-Carrie N, Farmachidid JP, Degott C, Guettier C, Trinchet JC, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131136.
  • 26
    McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945951.
  • 27
    Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558563.
  • 28
    Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911920.
  • 29
    Kamal SM, Turner B, Koziel MJ, Afdhal NH. YKL-40 and PIIINP correlate with the progression of fibrosis in chronic hepatitis C [Abstract]. Gastroenterology 2001; 120: 1895A.
  • 30
    Rosenberg W, Burt A, Hubscher S, Roskams T, Voekler M, Becka M, Arthur MJ. Serum markers predict liver fibrosis [Abstract]. Hepatology 2001; 34: 396A.
  • 31
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 10691075.
  • 32
    Merkel C, Bolognesi M, Finucci GF, Angeli P, Caregaro L, Rondana M, Gatra A. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989; 9: 1622.
  • 33
    Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260526.
  • 34
    Aube C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, Valsesia E, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472478.
  • 35
    Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R., Urbank A, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 15791583.
  • 36
    Hoefs JC, Wang F, Kanel G. Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol 1997; 92: 20542058.
  • 37
    Grace N. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997; 92: 10811091.